ArticleInternational journal of clinical and experimental pathology2018
Expression of vimentin and Oct-4 in gallbladder adenocarcinoma and their relationship with vasculogenic mimicry and their clinical significance.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- A peripheral blood-based approach involving vimentin along with AURKA enabled efficient tracking of elusive Oct4/Sox2-expressing disseminated breast cancer stem cells.Bioscience reports · 2026Article
- Global gene expression landscape of gallbladder cancer and advances in targeted therapeutic strategies.World journal of clinical oncology · 2025Review
- Breaking the bottlenecks in anti-tumor angiogenic therapy: targeting vasculogenic mimicry with natural products and traditional Chinese medicine.Frontiers in pharmacology · 2025Review
- Clinical Significance of Overexpression of Oct4 in Advanced Stage Gallbladder Carcinoma.Journal of gastrointestinal cancer · 2023Article
- The Evaluation of 17 Gastrointestinal Tumor Markers Reveals Prognosis Value for MUC6, CK17, and CD10 in Gallbladder-Cancer Patients.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vimentin (a marker of epithelial-mesenchymal transition), and Oct-4 (a marker of cancer stem cells) are predicative biomarkers for identifying malignant cell invasion and metastasis. Vasculogenic mimicry (VM), a newly discovered tumor characteristic that is common in highly invasive malignancies, is considered to be an important factor in evaluating the prognosis and metastasis of many malignancies. The following paper analyzes the correlation between vimentin, Oct-4, and VM in gallbladder adenocarcinoma (GBAC) specimens using immunohistochemistry in an attempt to elucidate the survival and clinicopathological parameters of changes in vimentin, Oct-4, and VM. Briefly, significantly higher positive expression rates of vimentin, Oct-4, and VM were observed in GBAC tissues than in the corresponding para-carcinoma tissues. In addition, the levels of vimentin, Oct-4, and VM were positively correlated with tumor grade, lymph node metastasis (LNM), infiltration of the surrounding tissues (STI), and tumor-node-metastasis (TNM) stage, as well as inversely with a patient's overall survival (OS) time. Moreover, the analysis of multiple factors shows that high vimentin, Oct-4, and VM levels, STI, and LNM as well as TNM stage were potential and significant factors for OS time in patients with GBAC. To sum up, the positive expression of vimentin, Oct-4, and VM may be undesirable factors for metastasis, invasion and prognosis, as well as effective therapeutic targets for GBAC.
Indexed as
Identifiers
31949742PMC6962874W3028198727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.